HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (59) Citing Articles via Google Scholar Google Scholar Articles by Fandrey, J. Search for Related Content PubMed PubMed Citation Articles by Fandrey, J.

INVITED REVIEW

Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression

Institut für Physiologie, Universitätsklinikum Essen, Universität Duisburg-Essen, D-45147 Essen, Germany

	ABSTRACT

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Hypoxia-inducible expression of the gene encoding for the glycoprotein hormone erythropoietin (EPO) is the paradigm of oxygen-regulated gene expression. EPO is the main regulator of red blood cell production and more than 100 years of research on the regulation of EPO production have led to the identification of a widespread cellular oxygen sensing mechanism. Central to this signaling cascade is the transcription factor complex hypoxia-inducible factor-1 (HIF-1). Meanwhile, it is known that HIF-1 controls more than 50 oxygen-dependent genes and is now recognized as the main regulator of oxygen homoeostasis in the body. In addition to hypoxic induction, expression of the EPO gene is tightly regulated in a tissue-specific manner. During ontogeny, production of EPO required for erythropoiesis is switched from the fetal liver to the kidneys. Here EPO is mainly synthesized in adulthood. Production of EPO has also been found in organs where it has nonerythropoietic functions: EPO is important for development of the brain and is neuroprotective, whereas it stimulates angiogenesis in the reproductive tract and possibly in other organs. Understanding oxygen and tissue-specific regulation of EPO production is of high relevance for physiology. Moreover, this knowledge might be useful for new therapies to treat human diseases.

hypoxia-inducible factor-1; hypoxia; oxygen sensing; prolyl hydroxylases

	HISTORY OF EPO

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
One of Claude Bernard's pupils, Paul Bert, known as the pioneer of aviation medicine, was the first to recognize an increase in the number of red blood cells at reduced barometric pressure and thus decreased PO₂ (8). He had studied animals living at high altitude and suspected a genetic reason for their elevated O₂ capacity of the blood. Viault (149) recognized that acute exposure to high altitude was stimulus enough to increase the number of erythrocytes during a 3-wk expedition to the Peruvian mountains. Almost 100 years ago, it was Paul Carnot and his research assistant Mlle. C. Deflandre (15) who first proposed humoral regulation of erythropoiesis by a "hemopoietin." Using serum from anemic rabbits, they reported an increase of red blood cell counts on injection into nonanemic recipient animals (15). However, due to the experimental conditions—their donor animals were only moderately challenged by mild anemia—their results were difficult to reproduce; details on that controversy in the beginning of erythropoietin research were very recently highlighted (39). In 1948, Bonsdorff and Jalavisto (11) coined the name "erythropoietin" for the humoral mediator of which the existence was proven by the classical parabiotic animal experiments performed by Ruhenstroth-Bauer (124) and Reissmann (121). In a landmark publication 50 years ago, Alan Erslev (31) unambiguously elicited reticulocytosis on injection of serum from anemic donor animals to prove the existence of EPO. In his publication, Erslev already envisioned the potential therapeutic value of EPO to treat anemia. Although it took another few decades to prove the successful treatment of an anemia caused by EPO deficiency with recombinant EPO (32, 154), many of the effects observed by Erslev foretold the later story of the successful use of EPO as a therapeutic agent. To obtain recombinant EPO, however, the tedious work of Miyake and colleagues (111) was a prerequisite. They purified human EPO from 2,550 liters of urine from severely anemic patients to allow the identification of initial parts of the amino acid sequence from tryptic fragments (111). From there, DNA probes were generated and the successful cloning of the EPO gene was reported by Lin et al. (93) and Jacobs et al. (66).

	OXYGEN-DEPENDENT PRODUCTION OF EPO

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Although steady-state production of EPO is necessary to maintain the physiological daily renewal of red blood cells, it is the stimulation by hypoxia on exposure to high altitude that promoted research on EPO from very early on (8, 68). It was necessary to understand that it is not the number of red blood cells itself that is sensed, but the blood O₂ content that in turn determines the oxygenation of EPO-producing tissues and thus EPO production. In general, plasma EPO protein concentrations show an inverse log/linear relationship with O₂ capacity of the blood. Thus acute hemorrhage, hemolysis, or insufficient erythropoiesis due to bone marrow failure all result in anemia and cause EPO levels to rise exponentially up to several hundred-fold of the normal concentration (33, 131). This increase is rapid and depends on de novo synthesis of EPO, which is not stored preformed in EPO-producing cells (68). Likewise, functional anemia caused by CO intoxication and/or other increases in O₂ affinity of hemoglobin (71) as well as reduced arterial PO₂ values under normobaric or hypobaric (high altitude) hypoxia strongly stimulate EPO production. Taken together, a reduced O₂ content of the blood results in tissue hypoxia, which is the proximate stimulus for expression of the EPO gene primarily in the adult kidneys and the fetal liver. Thus hypoxic activation of DNA sequences flanking the EPO gene control temporal-spatial regulation of EPO expression.

	REGULATORY DNA ELEMENTS IN THE EPO GENE

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
To identify these regulatory DNA sequences, Semenza and colleagues (135–137) generated a series of transgenic mice by introducing DNA fragments encompassing the human EPO gene into a mouse germ line by pronuclear microinjection. The shortest DNA fragment they injected was a 4-kb fragment (tgEPO4) that included all five exons and four introns of the human EPO gene as well as 0.4 kb of DNA upstream (5') to the transcription initiation site and 0.7 kb of DNA downstream (3') to the polyadenylation site (137). The fact that three noncoding regions of the EPO gene are highly conserved between the human and the mouse gene sequence suggested that they might contain regulatory DNA elements: the promoter, the first intron and a 120-bp region 3' to the polyadenylation site (43). Those sequences were included in the tgEPO4 construct and, indeed, expression in the liver of the transgenic mice was induced by anemia (137). Therefore, it was concluded that the transgene contained a liver inducible element (LIE in Fig. 1). However, these mice failed to show induction of EPO expression in the kidneys and had promiscuous expression of the transgene in organs where the mouse gene was not expressed physiologically. This indicated that the construct lacked some elements that restrict expression to the physiologically appropriate sites. Moreover, the majority of the mice were moderately polycythemic due to elevated serum EPO levels when compared with control nontransgenic animals (137). When the DNA constructs for injection were extended to 10 kb of human DNA by including additional 6 kb of 5' DNA (tgEPO10), liver inducibility was retained, but promiscuous expression was suppressed by a negative regulatory element (NRE in Fig. 1) (135). Within this 6-kb region, which shows a high degree of conservation compared with the mouse sequence, lie a considerable number of binding sites for transcription factors that may be involved in negative regulation of EPO expression (92). Extending the DNA fragment by another 8 kb to an 18-kb construct (tgEPO18) resulted in transgenic mice in which hypoxia and anemia induced the transgene in liver and kidney (136). Expression of the transgenes in the kidneys was localized to the correct physiological site, the interstitial peritubular cell population (136).

View larger version (21K): [in this window] [in a new window]   Fig. 1. Oxygen sensing and erythropoietin (EPO) gene expression. Bottom: EPO gene with its regulatory DNA elements. Depicted are the kidney-inducible element (KIE), the negative regulatory element (NRE), the 5'- and 3'-untranslated region (UTR), the liver-inducible element (LIE), and the negative regulatory liver element (NRLE). At higher magnification, the minimal promoter with the hypoxia associated factor (HAF) and the GATA binding sites is shown. Top: summary of the current concept of oxygen sensing and activation of hypoxia inducible factor (HIF)-1. Under normoxic conditions in the presence of O2, HIF-1 is hydroxylated at 2 specific proline residues by prolyl hydroxylase domain (PHDs) containing enzymes and at an asparagine (Asn803) by the factor inhibiting HIF-1 (FIH-1). Hydroxylation of Asn803 prevents the coactivator p300 from binding to the COOH terminus of HIF-1 and thus decreases transcriptional activity. Both PHDs and FIH-1 require O2. Hydroxyproline HIF-1 is recognized by the von-Hippel-Lindau protein (pVHL), ubiquitinated, and sent to proteasomal degradation. Under hypoxia, HIF-1 evades degradation and can bind as the HIF-1 dimer to the HIF binding site (HBS) within the hypoxia response element (HRE). This is shown as part of the LIE in greater detail at right top and also contains the CACA repeat and the 2 nuclear receptor half sites separated by 2 base pairs (DR-2). HNF, hepatocyte nuclear factor.

In addition, the conclusion may be drawn that kidney and liver hypoxia-responsive elements (HRE) of the EPO gene are different. For the kidney, the HRE is most likely located between 9.5 and 14 kb 5' of the gene (KIE). Description of a DNAse I hypersensitivity site between 14 and 9.5 kb 5' to the gene suggested a potential transcriptional factor binding site for renal expression (82). Although DNAse I hypersensitivity was increased by anemia this was not specific to nuclei from renal cells but also found in DNA from liver nuclei (82). Interestingly, part of the sequence hypersensitive to DNAse I resembled that of the consensus-binding site for HIF-1 similar to that lying in the 3' enhancer identified from liver cells (see below). Possibly, other tissue-specific factors bind to this DNA region and are required for hypoxia inducibility in the kidney.

Collectively, transgenic animal studies revealed the following. 1) Hypoxia inducibility elements for the liver (LIE, within 0.7 kb 3' to the gene) and the kidney (KIE, between 9.5 and 14 kb 5' to the gene) are located in flanking sequences at opposite ends of the gene. 2) Generally active repressive elements lie within 6 kb 5' to the gene (NRE). 3) A specific negative regulatory liver element (NRLE) is located between 2.2 and 7 kb 3' to the gene (Fig. 1).

	IN VITRO DISSECTION OF CIS-ACTING ELEMENTS OF THE EPO GENE

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Further analyses of the molecular mechanisms of hypoxia-induced EPO expression were hampered by the lack of an appropriate renal cell culture system resembling the regulation of EPO in vitro. However, in 1987 Nielsen et al. (115) and Goldberg et al. (47) identified two human liver tumor cell lines, HepG2 and Hep3B, that showed regulated expression of the EPO gene that was dependent of the pericellular PO₂ (33, 155). Even today, no renal cell lines with O₂-regulated EPO expression are available. Recently, two neuroblastoma cell lines, SH-SY5Y and Kelly, have been found to serve equally as cellular models for studying the molecular mechanisms of hypoxia-induced EPO expression in nonhepatic cells (143).

With the help of the hepatoma lines, putative hypoxia-activated regulatory DNA sequences of the EPO gene were tested in vitro. Nuclei isolated from tgEPO10 mice that had high hepatic expression under hypoxia revealed a DNAse I hypersensitivity site 3' of the EPO gene only in extracts from the liver but not from brain, kidney, or spleen (136). A 256-bp fragment spanning the DNAse I hypersensitivity site controlling a reporter gene was transfected into Hep3B cells. Detailed analyses of this fragment have led to the identification of a hypoxically inducible enhancer lying 120 bp 3' to the EPO polyadenylation site in a region highly conserved between human and mouse sequence (5, 120, 136). This cis-acting DNA element showed all typical features of a eukaryotic enhancer and was responsive to hypoxia, cobalt chloride, and iron chelation like the EPO gene in vivo but not to cyanide or 2-deoxyglucose (120).

Within this EPO enhancer three defined sites are important for the response to hypoxia (Fig. 1). At the 5'-end, the sequence CACGTGCT was the first to be identified as an HIF-1 binding site (HBS). Double-stranded oligonucleotides were used to demonstrate proteins from nuclear extracts from Hep3B cells that specifically bound only when the cells were challenged with hypoxia. Two protein complexes were identified, one bound constitutively and the other (HIF-1) was present only in hypoxic cells (138). Components of the constitutive complex are ATF-1 and CREB-1, but the role for hypoxia-regulated EPO expression has not yet been settled for these factors (87). In contrast, an intact HBS and HIF-1 binding are indispensable for hypoxia-induced EPO expression.

Seven base pairs further 3' of the HBS, a CACA repeat is found in the human EPO gene. Mutation of this site abrogates hypoxia-inducible activity of the enhancer, but so far no protein bound to this repeat has been identified. Interestingly, however, close to the HBS of the lactate dehydrogenase A gene, a similar site has been found in close proximity to the HIF-1 site (38).

The third site in the EPO enhancer is a direct repeat of two steroid receptor half sites separated by two base pairs, termed a DR-2 site (10). This DR-2 site is absolutely required for hypoxic regulation of the EPO gene and thus deserved detailed analysis. Direct repeats of steroid receptor half sites are known to bind nuclear receptors for hormones, but none of the known ligands significantly affected EPO expression through the DR-2 site (10). Screening for orphan receptors, however, revealed specific binding of hepatocyte nuclear factor-4 (HNF4). The functional importance of HNF4 binding was demonstrated by use of a dominant negative mutant of HNF4 that abolished EPO expression in Hep3B cells (44). It was hypothesized that HNF4 may play an important role for tissue-specific expression of EPO. During mouse development the retinoic acid receptor RXR, another member of the nuclear receptor family, binds to the DR-2 site, whereas fetal erythropoiesis is located in the liver (embryonic day E9.5-E11.5). From E11.5, HNF4-activity becomes dominant, competes out binding of RXR, and may initiate the switch from retinoic acid control to hypoxic control of EPO expression (97). In P19 embryonic carcinoma cells that produce EPO but not in an O₂-regulated manner, retinoic acid has also been found to bind to the DR-2 site and to increase expression of a reporter gene driven by the EPO enhancer as well as the endogenous EPO gene (78). More recently, oxygen-regulated expression of EPO was found in neuroblastoma cell lines that lack HNF4 or other HNF4 isoforms (143). Which factors substitute for HNF4 in these cells is still under active investigation. Because neuroblastoma cells may serve as a model for EPO expression in neuronal cells, the role for tissue-specific factors binding to the DR-2 site deserves further study.

Although the EPO promoter by itself is a weak promoter, it shows hypoxic inducibility and, moreover, acts synergistically with the enhancer to achieve a 50- to 100-fold stimulation in vitro and several hundred to even 1,000-fold stimulation in vivo (10, 68). The minimal EPO promoter encompasses 117 bp 5' to the transcription start site and has no consensus HBS. Proteins interacting with a 17 bp (nt –61 to –45) sequence designated EP17 synergize with transcription factors binding to the 3' enhancer of the EPO gene. Recently, this protein termed hypoxia-associated factor (HAF) was cloned and partially characterized (52). HAF is the murine homologue of Sart-1, a 125-kDa human protein recognized by cytotoxic T lymphocytes. HAF antisense treatment of Hep3B cells reduced hypoxia-induced EPO expression but did not abrogate basal expression, suggesting that HAF acts in conjunction with other transcription factors to modulate O₂-dependent EPO expression (52).

There appear to be some negative cis-acting elements in the promoter that repress EPO expression as well (Fig. 1). Whereas a ribonucleoprotein negatively regulating EPO expression has already been described several years ago but not further characterized (9), two GATA-sites have been extensively studied with respect to oxygen sensitivity, tissue specificity, and also their potential role during ontogeny (25, 62). Increased expression and binding of GATA-2 were found at high PO₂ in Hep3B cells, and overexpression of GATA-2 and -3 suppressed EPO expression (62). Hydrogen peroxide (H₂O₂), a potent inhibitor of EPO expression (34), was found to increase GATA-2 binding to the EPO promoter and may thus convert redox sensitivity to the EPO gene (Ref. 144 and see below). In contrast, it has just been reported that GATA-4 also binds to the promoter but increased EPO expression and may be required for hepatic expression during fetal development (26).

One further regulating mechanism of EPO expression that has not been fully elucidated in vivo is the role of methylation of CpG sites in the EPO promoter (152, 161). Methylation of CpGs in the promoter represses EPO expression by recruiting methyl CpG-binding proteins that can interfere with other transcription factors or recruit histone deacetylases and corepressors (161). In EPO-producing cells, these CPGs are less methylated that in non-EPO-producing cells (152, 161) and, at least for a CpG near the transcription start site, the methylation status appears to be partly influenced by hypoxia (161). Thus methylation of CpGs may effect tissue-specific EPO expression, but factors controlling the methylation state of the CpGs in the EPO promoter still need to be defined.

	EPO mRNA STABILITY

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
About 50% of the hypoxic increase of EPO mRNA can probably be attributed to increased transcription, leaving a significant contribution of mRNA stabilization to the total amount of cellular EPO mRNA. Studies on EPO mRNA half-life were always hampered by the fact that inhibitors of transcription markedly prolong the half-life of the EPO mRNA (57). By use of a marked EPO gene, however, a sevenfold increase of the half-life of EPO mRNA on hypoxia was found that depended on the lack of binding of destabilizing EPO mRNA binding proteins (ERBP) under normoxia to a pyrimidine-rich region in the 3'-untranslated region (UTR) of the EPO mRNA (57). Activity of the sequence appears to depend on p38 MAP kinase activity (145). The importance of this stress kinase as well as the stabilization of EPO mRNA for hypoxia-induced EPO synthesis is underlined by the finding that p38^–/– mice showed a phenotype that was comparable to EPO^–/– embryos (158). In fact, p38^–/– embryos die in midgestation due to anemia (145).

	HIF-1

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Thorough studies on the 3' enhancer of the EPO gene have probably led to the most interesting and important finding that originates from basic research on understanding the regulation of EPO production: the evidence that hypoxia-induced EPO gene expression is under control of a widespread oxygen-sensing mechanism (107). Transfection of the EPO enhancer into non-EPO-producing cells clearly showed that the enhancer could fully operate and respond to hypoxia irrespective of whether the cells produced EPO (107). Moreover, mimics of hypoxia, cobalt chloride and iron chelators, were fully active but not chemical hypoxia caused by agents such as cyanide.

Analysis of the proteins bound to the 3' EPO enhancer revealed a protein complex termed HIF-1 of which the binding was essential for hypoxic induction of the EPO gene (138). Affinity purification using DNA binding of this complex and subsequent cloning resulted in the identification of a protein heterodimer consisting of the two basic-helix-loop-helix PAS proteins HIF-1 and HIF-1 (150). Although the 120-kDa -subunit was entirely new in sequence, the 91- to 94-kDa -subunit turned out to be identical with aryl hydrocarbon receptor nuclear translocator (ARNT), the dimerization partner of dioxin receptor (AHR, aryl hydrocarbon receptor) (150). Both the - and -subunit are members of the PAS protein family where the acronym PAS stands for the first three members of this family of transcription factors Per/ARNT/Sim (for a review on PAS proteins, see Ref. 50).

Steady-state levels of HIF-1 and HIF-1 mRNA are not significantly affected by hypoxia compared with the great increase in cellular HIF-1 protein content under hypoxia (156). In fact, hypoxia inducibility of the HIF-1 complex is solely achieved by hypoxic accumulation of the -protein subunit, whereas the -subunit is constitutively expressed. In normoxic cells, HIF-1 is barely detectable due to rapid degradation via the ubiquitin proteasome pathway (60, 127). HIF-1 is continuously synthesized irrespective of the oxygenation status of the cells. This provides a very rapid response of HIF-1 accumulation when hypoxia occurs, simply by blocking the degradation of the protein, and allows an almost instantaneous response to hypoxia by accumulation of HIF-1 without activating the transcriptional/translational machinery (72). Therefore, the search for the oxygen-sensing mechanism was focused on the rapid degradation of HIF-1 under normoxia. Maxwell and colleagues (108) first described the critical role of the tumor suppressor protein von Hippel-Lindau (VHL) for this degradation process. VHL protein was found to bind to the two oxygen-dependent degradation domains (ODD) of HIF-1 that had previously been described to confer oxygen-dependent instability on the HIF-1 protein and also on other proteins fused with the ODD (60, 73, 118). In addition, it turned out that HIF-1 protein abundance—regulated via the ODD and normoxic degradation—as well as its trans-activity via an NH₂-terminal and a COOH-terminal transactivating domain (N-TAD and C-TAD, respectively) was independently regulated by oxygen (28, 116). Whereas this already indicated regulation of HIF-1 at multiple molecular levels, cellular localization of HIF-1 also appeared to be O₂ dependent, because translocation from the cytosol to the nucleus was increased under hypoxia (77).

	OXYGEN SENSING THROUGH POSTTRANSLATIONAL MODIFICATION OF HIF-

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Study of the role of VHL for HIF-1 degradation provided the new focus for analysis of oxygen-sensitive pathways. Cells deficient in functional VHL accumulate large amounts of HIF-1 irrespective of their oxygenation status (108). Each of the two ODDs contains the amino acid proline embedded into the common LxxLxP motif for hydroxylation (101). Different peptides comprising HIF-1 sequences were used to study the interaction with VHL and revealed that enzymatic hydroxylation of HIF-1 at proline residues 564 and 402 (in human HIF-1) was necessary for recognition by VHL (63, 65, 101). VHL bound to HIF-1 then recruits other components of the E3 multicomponent ubiquitin ligase that tags HIF-1 for subsequent proteasomal degradation (142). On the basis of Caenorhabditis elegans genetics, Epstein et al. (30) succeeded in the cloning of the mammalian HIF prolyl hydroxylases that were designated "prolyl hydroxylase domain" containing (PHD) 1, 2, and 3 (30). Independently, Bruick and McKnight (13) identified three HIF-prolyl hydroxylases (termed HPH3, 2, and 1, respectively) based on their close relationship to collagen-modifying prolyl hydroxylases.

The activity of PHDs depends on the availability of oxygen and thus qualifies these enzymes as O₂ sensors. Recently, the O₂ affinity has been determined and suggests appropriate sensitivity in the physiological relevant PO₂ range (56). In addition, these dioxygenases require 2-oxoglutarate as cosubstrate and vitamin C to keep their central non-heme iron in the ferrous state. O₂ binds to this central moiety and is split, with one oxygen atom being incorporated into the proline residue of HIF-1 and the second reacting with 2-oxoglutarate to yield succinate and CO₂. Under hypoxia, activity of the enzymes is greatly reduced, the specific proline residues in HIF- are no longer hydroxylated, and HIF- subunits can accumulate to activate HIF-1-dependent genes like EPO. Hypoxia-mimicking induction of EPO by cobalt chloride or iron chelators may also be explained by effects on the PHDs, because these chemicals may either substitute for (cobalt chloride) or chelate the central iron and inactivate the prolyl hydroxylases like hypoxia (151).

Interestingly, the C-TAD is also modulated by an O₂-sensitive hydroxylation step, this time, however, on the asparagine residue 803 [in human HIF-1 (90)]. Here, hydroxylation of asparagine under high oxygen pressure inhibits recruitment of the transcriptional coactivator CBP/p300 (3, 128) necessary for hypoxic HIF-1 activity. This asparagine hydroxylase had been identified earlier as factor inhibiting HIF-1 (FIH-1), because its interaction, hydroxylation of asparagine N803, inhibited the trans-activity of HIF-1 (96). FIH-1-like PHDs turned out to be a 2-oxoglutarate-dioxygenase requiring O₂ and iron for its function (55, 89). The recent localization of PHDs (59) and FIH-1 (109) in different cellular compartments and the inducibility of the enzymes themselves by hypoxia (30, 109) as well as the differences in O₂ affinities between PHDs and FIH-1 (56, 83) are currently promoting studies on the regulation of the activity of these potential cellular O₂ sensors.

In addition to the O₂-dependent hydroxylation, phosphorylation by p42/p44 (Erk2/Erk1) mitogen-activated protein kinases (MAPKs) of HIF-1 (and HIF-2; see below) is required for transcriptional activity (20, 122). Although phosphorylation does not appear to be O₂ regulated and the exact phosphorylation sites have not yet be defined, this posttranslational modification may allow to modulate HIF-1 activity by other cellular signaling pathways (151). Likewise, receptor tyrosine kinase-PI3-kinase-PTEN-Akt kinase signaling is critically involved in HIF-1 regulation but rather by increasing HIF1- translation than protein stability (see Refs. 12, 102, 151 for further references).

Taken together, O₂-dependent regulation of HIF- (these mechanisms also regulate the other two known members of the HIF family, HIF-2 and HIF-3; see below) resembles many if not all the features characteristic for physiological regulation of EPO by hypoxia. A defect in the degradation of HIF- caused by a mutation in VHL leads to polycythemia due to increased expression of the HIF-1 target EPO. Hypomorphic VHL alleles have recently been detected in congenital Chuvash polycythemia, underlining the importance of proper HIF regulation for the control of EPO production (2).

Today, more than two dozen oxygen-regulated HIF-1 target genes with critical importance for physiology and pathophysiology of ischemic disease and tumor biology are known. Thus HIF-1 has been recognized as the master regulator of O₂ homeostasis (132). For further details on HIF, the reader is referred to some recent reviews (12, 119, 139, 151).

	WHICH HIF- IS REGULATING EXPRESSION OF THE EPO GENE?

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
HIF-1 is ubiquitously expressed but is not the only member of this subfamily of PAS proteins. HIF-2 (29, 41, 58, 147) and HIF-3 (51) partly overlap with HIF-1 in their expression pattern, but assignment of specific functions to the different HIF-s has not yet been achieved. Knockout mice for HIF-1 and HIF-2 dramatically differ in their phenotype. Whereas HIF-1^–/– mice die around midgestation due to severe cardiovascular and central nervous system (CNS) malformations (64, 125), three different phenotypes for HIF-2^–/– mice (perhaps depending on the genetic background) were observed (18, 117, 148). Although one HIF-2^–/– mouse evidently died of bradycardia because the organ of Zuckerkandl responsible for catecholamine synthesis during development was not productive, one other HIF-2^–/– mouse showed gross deficits in remodeling of the primary vascular network (117, 148). A third phenotype was observed where the mice died after birth due to a respiratory distress syndrome caused by insufficient surfactant production from type II alveolar cells (18). From all those animals no clear conclusions with respect to defects in EPO expression could be drawn. In contrast, mice containing only one mutant HIF-1 allele (HIF-1^+/– mice) developed normally but, among other impaired physiological responses to hypoxia, these mice had delayed erythrocytosis on exposure to hypoxia (163). Although HIF-2 and HIF-3 may interact with the HIF-1-binding site and could also compete for dimerization partners, the data from Yu et al. (163) suggest a dominant role for HIF-1 for EPO regulation.

Recently Rosenberger et al. (123) studied the expression pattern of HIF-1 and HIF-2 in hypoxic rat kidneys. Because only HIF-2 was localized in the peritubular fibroblasts that produce EPO, the authors proposed a role for HIF-2 in hypoxic rat kidneys in the regulation of the EPO gene (123). This hypothesis is supported by a study on the retinopathy of prematurity to which expression of EPO in the retina significantly contributes (112). In this study, HIF-2 knockdown, i.e., reduction of HIF-2 expression to about one-fifth of the normal level, lowered EPO expression induced by relative hypoxia that was not compensated by unchanged HIF-1 accumulation (112). In contrast, light-induced retinal degeneration was reported to be prevented by hypoxia-induced EPO expression in the retina that coincided with increased HIF-1 levels (49).

Thus in vivo studies do not provide firm evidence which HIF- controls EPO mRNA expression. Although HIF-1 was cloned from binding to the HBS of the EPO gene in human hepatoma cells, these cells also express HIF-2. Therefore, there may be cell- and organ-specific differences and/or different affinities of HIF-1 and -2 for the HBS in the EPO gene that depend on other transcription factors that help to form the HIF-1 complex (see above). At least in vitro, overexpression and activation of HIF-1 and -2 can activate the EPO enhancer by forming an active HIF-1 complex (28). A definite answer as to which HIF- controls EPO expression still awaits experimental evidence.

	TISSUE-SPECIFIC EPO EXPRESSION

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Two further questions with respect to tissue-specific expression of EPO await answers: the developmental switch from expression of EPO in the fetal liver to renal expression in the adult and the expression in organs where synthesized EPO does not play a role as an erythropoietic hormone but more that of a paracrine protective factor.

Adult expression of EPO in mammals is primarily localized in the kidney as first demonstrated by the classical organ ablation studies by Jacobson et al. (67). Before birth, however, the fetal liver is the main production site (165). Although species differences in the timing of the switch and the degree of contribution of the liver to total body EPO mRNA content exist (for review, see Ref. 113), the switch is undoubtedly found in humans as well (23). The mechanism and the main factors determining the switch still remain to be identified, but recent data indicate that GATA-4 may be one of the factors that specifically promotes EPO expression in the liver (26). Fetal expression of EPO is present in all lobes of the human liver (23) and EPO-expressing cells in the liver—hepatocytes and Ito cells (86, 105)—display an expression pattern that follows the PO₂ distribution (74): high expression around central veins at lower PO₂ values and expression extending to the periportal field on anemia or hypoxia (86). Because the hepatic expression appears so strictly regulated by the PO₂ gradient, a major role for changes of this gradient around birth has been proposed to control the switch (for review, see Ref. 113). However, as pointed out above, specific sequences in the regulatory DNA elements that are different for the kidney and the liver regulate expression presumably through the binding of tissue and developmental specific transcription factors (44, 97). Moreover, although changes in the oxygenation around birth are similar in different species, the switches differ significantly with respect to birth date (113). Finally, surgical procedures aimed at reducing hepatic or renal oxygenation do not significantly affect the switch (40). It is, however, of interest that liver cells retain their capacity for high EPO expression in an adult environment as documented by the transgenic mice studies performed by Semenza et al. (137). Thus it is very likely that tissue factors in the adult kidney may well arise around birth that are indispensable for EPO expression and repressive factors are expressed in the liver of the adult.

This is underlined by the fact that, so far, the isolation of renal EPO-producing cells and the setup of renal cell lines for studies of the regulated expression of EPO have not been successful. EPO-expressing cells in the kidney have been identified as fibroblast-like type 1 interstitial cells filling the peritubular space in the cortex and outer medulla (4, 106). There has been some debate about the identity of the cell expressing EPO in the kidney that has recently been highlighted extensively (39). Particularly interesting is a major difference between liver and kidney after challenge with hypoxia. Whereas the amount of EPO mRNA per hepatocyte appears to rise on hypoxia, in the kidney an increasing number of cells with fixed EPO mRNA content is recruited (85, 86). Whether this is caused by tissue-specific factors or potentially different HIF- isoforms (see above) or oxygen gradients needs to be determined. Although this hepatocyte characteristic response is reflected by the hepatoma cells available for in vitro studies (33), the isolation of renal EPO-producing cells remains an important aim.

Much recent attention has been paid to EPO expression in other organs, particularly in the brain (22, 33, 98, 146) and the reproductive tract (81, 104, 146, 160).

EPO expression in the CNS has recently been proposed to be central for normal brain development (164), although in an earlier study mice with an EPO gene knockdown were neurologically normal (105). EPO has been found to be neuroprotective (7, 103, 126, 140) and has opened a rapidly developing field that deserves much more attention than can be paid here due to space limitations. The reader is referred to some very recent reviews (24, 99 and references therein). EPO expression in the CNS is also found in the human fetus early in gestation (22, 75). Interestingly, although the expression is stimulated by hypoxia, such as in the kidneys or the liver, the temporal pattern is significantly different (17). Whereas EPO expression in kidneys and liver on hypoxia is transient, peaking 6–24 h in vivo (depending on the severity of hypoxia; see Ref. 68 for references) and at 6 h in vitro (33), EPO mRNA levels remain elevated in the brain for the duration of the hypoxic stimulus (17). Even relative hypoxia keeps EPO mRNA levels up at least for 12 h (112), and it has been argued that the paracrine neuroprotective effect of EPO should require expression for the duration of the hypoxic stress to be effective (129). In vitro studies revealed that expression in hepatic and neuronal cells similarly shows a high degree of redox sensitivity of the EPO gene (6, 34). The recent availability of neuronal-like cell lines with regulated expression of EPO suggests significant differences (143). Whereas HNF-4 was indispensable for hepatic expression (Ref. 44 and see above), neuroblastoma cells express the EPO gene in an oxygen-dependent manner in the absence of HNF-4 (143). EPO expression is under control of the HIF-1 complex, but ARNT-2, an isoform of HIF-1 (= ARNT-1) that is specifically expressed in the kidney and brain (27) contributes to the HIF-1 complex in these neuroblastoma cells (143). Moreover, preliminary data from experiments with these cells suggest a role for HIF-1 but not HIF-2 in hypoxic regulation (U. Berchner-Pfannschmidt and J. Fandrey, unpublished). That would indicate important differences compared with kidney EPO expression (123).

An interesting feature that is paralleled by EPO expression in the brain and the testis (81, 95, 146) is the fact that EPO production at these sites may be separated from the systemic circulation by the blood-brain or blood-testis barrier, respectively. This fact would suggest a more paracrine than endocrine mode of action of EPO produced at these locations (21). However, EPO is also supposed to cross the blood-brain barrier (140), in particular after brain damage, and some animal studies suggest that systemic application may also affect testicular function (159). Notably a testis-specific isoform of HIF-1 has recently been described that could add a new level of complexity to tissue-specific regulation of EPO expression (100).

For the female reproductive tract, regulated expression of EPO in the uterus (160) and the oviduct of the mouse (104) has been found. Although controversial results for the rat have recently been reported (114), the human endometrium expresses EPO throughout the menstrual cycle, with higher levels in the secretory than in the proliferative phase (162). This is in line with the stimulatory effect of 17-estradiol (E₂) on EPO expression in the mouse oviduct and uterus (104, 160). The regulation by E₂ may be another tissue-specific feature of EPO regulation, because E₂ does not affect hypoxia-induced EPO expression in the brain or kidney but is indispensable for hypoxic inducibility in the uterus (17). Hypoxic induction in the uterus in the presence of E₂ was transient as in the kidneys but peaking earlier (2 h uterus vs. 6 h in the kidneys); comparable kinetics were found for the E₂ effect. Thus, for the uterus, the transient expression of EPO may just be a consequence of the fading E₂ stimulation that was necessary for hypoxic stimulation (17). In this way, tissue-specific and temporary regulation is interconnected. Functionally, EPO appears to play an important role for endometrial angiogenesis and thus reproductive function (160).

EPO mRNA expression has been found in the human, murine, and ovine placenta as well as on both the maternal and the fetal side (19, 80, 84, 153). Whereas this may explain EPO protein detection in amniotic fluid, a clear-cut fetal function—whether paracrine or endocrine—of EPO has not yet been determined. EPO has been described to exert a trophic effect on the fetal gastrointestinal tract when taken up enterally from the amniotic fluid (76).

Highly sensitive mRNA detection methods have revealed EPO mRNA expression in other organs such as the lung, spleen, the heart, and the bone marrow (33). Not for all these locations has the synthesis of EPO protein been unambiguously documented, but expression in the bone marrow appears to be involved in an auto-/ or paracrine loop of erythropoiesis. However, the importance of paracrine EPO is certainly significantly lower than that of systemic EPO levels for erythropoiesis as evident from the renal anemia in terminal kidney disease. For the heart, EPO appears to be necessary for proper cardiac morphogenesis (157), although expression of EPO in the heart appears to be very low. It is still questioned whether EPO from the heart itself can protect the myocardium from ischemia reperfusion injury (14), which can be achieved by systemic application of EPO (14). Taken together, many questions regarding tissue-specific expression, particularly different isoforms of HIF-1 or additional transcription factors that modulate hypoxia-induced expression, remain unanswered. Once more, studies beyond its erythropoietic function make EPO an attractive field of clinical research.

	FACTORS NEGATIVELY REGULATING EPO GENE EXPRESSION

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
The finding that H₂O₂ inhibits EPO expression has fueled the discussion on oxygen-sensing and O₂-dependent gene expression for some time (34). On the basis of the work of Goldberg and colleagues (46) suggesting that the oxygen sensor might be a heme protein, a role for b-type cytochromes in O₂-dependent EPO expression was investigated (35). Subsequent studies revealed a nonmitochondrial heme protein in HepG2 cells of which the spectral properties changed on oxygenation (48). The spectral properties were similar to the O₂^–-generating NADPH oxidases, and, indeed, an inverse relationship of H₂O₂ (dismutated from O₂^–) and EPO expression was found (34). Because exogenous H₂O₂ inhibited EPO expression mimicking high PO₂, and scavenging of high H₂O₂ increased EPO expression despite high PO₂, a role for H₂O₂ as a signaling molecule in O₂ sensing was proposed. In subsequent work by Huang et al. (61), H₂O₂ reduced HIF-1 and thus reduced the hypoxic induction. Although redox sensitivity of the HIF-1 complex has been confirmed (91) changes in reactive O₂ species (ROS) levels in response to changes in PO₂ have been controversial (16). In part, conflicting results may be the result of cell-specific effects or be explained by different culture conditions and detection systems for ROS (79). Rapid progress in the work on prolyl hydroxylase-dependent modification of HIF- that depends on the PO₂ instead of ROS (see above) has been made since. Undoubtedly, PHDs appear to sense O₂ directly. The inhibition of EPO expression by ROS has been shown to occur through activation of GATA-2, which acts as a repressor of the EPO gene (62). Still redox chemistry may be involved in an O₂-sensing process indicated by the fact that the central iron atom of PHDs and FIH-1 undergoes redox cycling and critically needs vitamin C for proper function (56, 102).

Affecting the redox state may indeed play a role in the recent report of direct inhibition of PHDs by NO (110). Interestingly, however, the increase in HIF-1 levels and activity by NO is apparently in conflict with the inhibition of EPO expression and decrease of HIF-1 by NO in some studies (130, 141). Although NO affects ROS levels and EPO expression in HepG2 and Hep3B cells, the exact mechanisms of inhibition of EPO production in the face of an increase of HIF-1 activity have not been resolved (45). Very recent work indicates that inhibition of mitochondrial respiration by NO might cause a redistribution of O₂ from the mitochondria to the cytosol and could thus interfere with HIF-1 regulation (53). Likewise, the inhibition of EPO expression by proinflammatory cytokines (36, 70), which contributes to the anemia of chronic inflammatory and malignant disease (69), is still not well understood. Although proinflammatory cytokines potently inhibit EPO expression in vitro and in vivo (42, 70), they induce HIF-1 and some HIF-1-dependent genes (54). Again, other transacting factors such as nuclear factor-B may be responsible for mediating the repressive effect on the EPO gene that overcomes hypoxia-induced and HIF-dependent induction (37, 88). In general, elucidation of the inhibition of EPO expression was intended to improve the understanding of the founding mechanisms that regulate physiological signaling during hypoxia. Instead, by acting on different positive and negative cis-acting elements, these inhibitory factors add another level of complexity for the understanding of the regulation of EPO gene expression by hypoxia.

	CONCLUDING REMARKS

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Studying EPO production in the past almost 100 years has enabled physiologists to get an understanding of O₂ sensing with respect to oxygen-dependent gene expression. HIF-1 is today acknowledged as the master regulator of oxygen homeostasis (132). HIF-1 was discovered as a trans-acting factor complex bound to cis-acting DNA elements of the EPO gene. Unraveling the activation back from HIF-1 has led to the identification of PHDs, today's most likely cellular oxygen sensors. Animals deficient for the PHD isoenzymes will provide definite proof of their importance. Although these studies are on the way, it is clear that HIF-1 also affects other systems of O₂ sensing such as the carotid body or the pulmonary vessels (163). It is the research on the regulation of EPO expression that has paved the way for many fascinating things to learn in the future.

	GRANTS

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 
Work in my lab is supported by the Deutsche Forschungsgemeinschaft (DFG Fa 225/18-20).

	ACKNOWLEDGMENTS

 
I thank C. Dame, W. Jelkmann, E. Metzen, and P. Ratcliffe for critically reviewing this manuscript.

	FOOTNOTES

 

Address for reprint requests and other correspondence: J. Fandrey, Institut für Physiologie, Universität Duisburg-Essen, Hufelandstr. 55, D-45147 Essen, Germany (E-mail: joachim.fandrey{at}uni-essen.de).

	REFERENCES

TOP ABSTRACT HISTORY OF EPO OXYGEN-DEPENDENT PRODUCTION OF... REGULATORY DNA ELEMENTS IN... IN VITRO DISSECTION OF... EPO mRNA STABILITY HIF-1 OXYGEN SENSING THROUGH... WHICH HIF-{alpha} IS REGULATING... TISSUE-SPECIFIC EPO EXPRESSION FACTORS NEGATIVELY REGULATING... CONCLUDING REMARKS GRANTS REFERENCES

 

1. Acker H. Mechanisms and meaning of cellular oxygen sensing in the organism. Respir Physiol 95: 1–10, 1994.[CrossRef][Web of Science][Medline]
2. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, and Prchal JT. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614–621, 2002.[CrossRef][Web of Science][Medline]
3. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, and Livingston DM. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969–12973, 1996.[Abstract/Free Full Text]
4. Bachmann S, Le Hir M, and Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41: 335–341, 1993.[Abstract]
5. Beck I, Ramirez S, Weinmann R, and Caro J. Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem 266: 15563–15566, 1991.[Abstract/Free Full Text]
6. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, Mackenzie ET, and Petit E. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30: 271–278, 2000.[CrossRef][Web of Science][Medline]
7. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, Mackenzie ET, and Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19: 643–651, 1999.[Web of Science][Medline]
8. Bert P. Sur la richesse en hémoglobine du sang des animaux vivant sur les hauts lieux. C R Acad Sci Paris 94: 805–807, 1882.
9. Beru N, Smith D, and Goldwasser E. Evidence suggesting negative regulation of the erythropoietin gene by ribonucleoprotein. J Biol Chem 265: 14100–14104, 1990.[Abstract/Free Full Text]
10. Blanchard KL, Acquaviva AM, Galson DL, and Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 12: 5373–5385, 1992.[Abstract/Free Full Text]
11. Bonsdorff E and Jalavisto E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 16: 150–170, 1948.
12. Bracken CP, Whitelaw ML, and Peet DJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60: 1376–1393, 2003.[CrossRef][Web of Science][Medline]
13. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337–1340, 2001.[Abstract/Free Full Text]
14. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, and Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108: 79–85, 2003.[Abstract/Free Full Text]
15. Carnot P and Deflandre C. Sur l'activité hémopoiétique du sérum au cours de la régénération du sang. C R Acad Sci Paris 143: 384–386, 1906.
16. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, and Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95: 11715–11720, 1998.[Abstract/Free Full Text]
17. Chikuma M, Masuda S, Kobayashi T, Nagao M, and Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab 279: E1242–E1248, 2000.[Abstract/Free Full Text]
18. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, and Carmeliet P. Loss of HIF-2 and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8: 702–710, 2002.[Web of Science][Medline]
19. Conrad KP, Benyo DF, Westerhausen-Larsen A, and Miles TM. Expression of erythropoietin by the human placenta. FASEB J 10: 760–768, 1996.[Abstract]
20. Conrad PW, Freeman TL, Beitner-Johnson D, and Millhorn DE. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J Biol Chem 274: 33709–33713, 1999.[Abstract/Free Full Text]
21. Dame C. Molecular biology of the erythropoietin receptor in hematopoietic and non-hematopoietic tissues. In: Erythropoietin and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology, edited by Molineux G, Foote M, and Elliott SG. Berlin: Birkhäuser Verlag, 2003, p. 35–64.
22. Dame C, Bartmann P, Wolber E, Fahnenstich H, Hofmann D, and Fandrey J. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res Dev Brain Res 125: 69–74, 2000.[Medline]
23. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P, and Fandrey J. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92: 3218–3225, 1998.[Abstract/Free Full Text]
24. Dame C, Juul SE, and Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 79: 228–235, 2001.[CrossRef][Web of Science][Medline]
25. Dame C, Sola MC, Fandrey J, Rimsza LM, Freitag P, Knopfle G, Christensen RD, and Bungert J. Developmental changes in the expression of transcription factors GATA-1, -2 and -3 during the onset of human medullary haematopoiesis. Br J Haematol 119: 510–515, 2002.[CrossRef][Web of Science][Medline]
26. Dame C, Sola MC, Lim KC, Leach KM, Fandrey J, Ma Y, Knopfle G, Engel JD, and Bungert J. Hepatic erythropoietin gene Regulation by GATA-4. J Biol Chem 279: 2955–2961, 2004.[Abstract/Free Full Text]
27. Drutel G, Kathmann M, Heron A, Schwartz JC, and Arrang JM. Cloning and selective expression in brain and kidney of ARNT2 homologous to the Ah receptor nuclear translocator (ARNT). Biochem Biophys Res Commun 225: 333–339, 1996.[CrossRef][Web of Science][Medline]
28. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1 in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905–1914, 1999.[CrossRef][Web of Science][Medline]
29. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273–4278, 1997.[Abstract/Free Full Text]
30. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43–54, 2001.[CrossRef][Web of Science][Medline]
31. Erslev AJ. Humoral regulation of red cell production. Blood 8: 349–357, 1953.[Abstract/Free Full Text]
32. Eschbach JW, Egrie JC, Downing MR, Browne JK, and Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73–78, 1987.[Abstract]
33. Fandrey J and Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood 81: 617–623, 1993.[Abstract/Free Full Text]
34. Fandrey J, Frede S, and Jelkmann W. Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 303: 507–510, 1994.[Web of Science][Medline]
35. Fandrey J, Seydel FP, Siegers CP, and Jelkmann W. Role of cytochrome P450 in the control of the production of erythropoietin. Life Sci 47: 127–134, 1990.[CrossRef][Web of Science][Medline]
36. Faquin WC, Schneider TJ, and Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79: 1987–1994, 1992.[Abstract/Free Full Text]
37. Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, and Beckman BS. NF-B plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 30: 1419–1427, 2002.[CrossRef][Web of Science][Medline]
38. Firth JD, Ebert BL, and Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270: 21021–21027, 1995.[Abstract/Free Full Text]
39. Fisher JW. From the elusive "Hemopoietine" to the anti-anemic drug rErythropoietin. In: Erythropoietin: Molecular Biology and Clinical Use, edited by Jelkmann W. Johnson City, TN: Graham, 2003, p. 3–32.
40. Flake AW, Harrison MR, Adzick NS, and Zanjani ED. Erythropoietin production by the fetal liver in an adult environment. Blood 70: 542–545, 1987.[Abstract/Free Full Text]
41. Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, and Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 and developmentally expressed in blood vessels. Mech Dev 63: 51–60, 1997.[CrossRef][Web of Science][Medline]
42. Frede S, Fandrey J, Pagel H, Hellwig T, and Jelkmann W. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol Regul Integr Comp Physiol 273: R1067–R1071, 1997.[Abstract/Free Full Text]
43. Galson DL, Tan CC, Ratcliffe PJ, and Bunn HF. Comparison of the human and mouse erythropoietin genes shows extensive homology in the flanking regions. Blood 82: 3321–3326, 1993.[Abstract/Free Full Text]
44. Galson DL, Tsuchiya T, Tendler DS, Huang LE, Ren Y, Ogura T, and Bunn HF. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 15: 2135–2144, 1995.[Abstract]
45. Genius J and Fandrey J. Nitric oxide affects the production of reactive oxygen species in hepatoma cells: implications for the process of oxygen sensing. Free Radic Biol Med 29: 515–521, 2000.[CrossRef][Web of Science][Medline]
46. Goldberg MA, Dunning SP, and Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242: 1412–1415, 1988.[Abstract/Free Full Text]
47. Goldberg MA, Glass GA, Cunningham JM, and Bunn HF. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 84: 7972–7976, 1987.[Abstract/Free Full Text]
48. Görlach A, Holtermann G, Jelkmann W, Hancock JT, Jones SA, Jones OTG, and Acker H. Photometric characteristics of haem proteins in erythropoietin-producing hepatoma cells (HepG2). Biochem J 290: 771–776, 1993.[Web of Science][Medline]
49. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, and Reme CE. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8: 718–724, 2002.[CrossRef][Web of Science][Medline]
50. Gu YZ, Hogenesch JB, and Bradfield CA. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40: 519–561, 2000.[CrossRef][Web of Science][Medline]
51. Gu YZ, Moran SM, Hogenesch JB, Wartman L, and Bradfield CA. Molecular characterization and chromosomal localization of a third -class hypoxia inducible factor subunit, HIF3. Gene Expr 7: 205–213, 1998.[Web of Science][Medline]
52. Gupta M, Mungai PT, and Goldwasser E. A new transacting factor that modulates hypoxia-induced expression of the erythropoietin gene. Blood 96: 491–497, 2000.[Abstract/Free Full Text]
53. Hagen T, Taylor CT, Lam F, and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1. Science 302: 1975–1978, 2003.[Abstract/Free Full Text]
54. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, and Jelkmann W. Interleukin-1beta and tumor necrosis factor- stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561–1567, 1999.[Abstract/Free Full Text]
55. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, and Schofield CJ. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277: 26351–26355, 2002.[Abstract/Free Full Text]
56. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, and Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278: 30772–30780, 2003.[Abstract/Free Full Text]
57. Ho V, Acquaviva A, Duh E, and Bunn HF. Use of a marked erythropoietin gene for investigation of its cis-acting elements. J Biol Chem 270: 10084–10090, 1995.[Abstract/Free Full Text]
58. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, and Bradfield CA. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272: 8581–8593, 1997.[Abstract/Free Full Text]
59. Huang J, Zhao Q, Mooney SM, and Lee FS. Sequence determinants in hypoxia-inducible factor-1 for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 277: 39792–39800, 2002.[Abstract/Free Full Text]
60. Huang LE, Gu J, Schau M, and Bunn HF. Regulation of hypoxia-inducible factor 1 is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987–7992, 1998.[Abstract/Free Full Text]
61. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its subunit. J Biol Chem 271: 32253–32259, 1996.[Abstract/Free Full Text]
62. Imagawa S, Yamamoto M, and Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 89: 1430–1439, 1997.[Abstract/Free Full Text]
63. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr. HIF targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. Science 292: 464–468, 2001.[Abstract/Free Full Text]
64. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, and Semenza GL. Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 . Genes Dev 12: 149–162, 1998.[Abstract/Free Full Text]
65. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF- to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. Science 292: 468–472, 2001.[Abstract/Free Full Text]
66. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, and Fritsch EF. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806–810, 1985.[CrossRef][Medline]
67. Jacobson LO, Goldwasser E, Fried W, and Plzak L. Role of the kidney in erythropoiesis. Nature 179: 633–634, 1957.[CrossRef][Medline]
68. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449–489, 1992.[Free Full Text]
69. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18: 555–559, 1998.[Web of Science][Medline]
70. Jelkmann W, Pagel H, Wolff M, and Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50: 301–308, 1992.[CrossRef][Web of Science][Medline]
71. Jelkmann W and Seidl J. Dependence of erythropoietin production on blood oxygen affinity and hemoglobin concentration in rats. Biomed Biochim Acta 46: S304–S308, 1987.[Web of Science][Medline]
72. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, and Gassmann M. Induction of HIF-1 in response to hypoxia is instantaneous. FASEB J 15: 1312–1314, 2001.[Free Full Text]
73. Jiang BH, Zheng JZ, Leung SW, Roe R, and Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272: 19253–19260, 1997.[Abstract/Free Full Text]
74. Jungermann K and Katz N. Functional specialization of different hepatocyte populations. Physiol Rev 69: 708–764, 1989.[Abstract/Free Full Text]
75. Juul SE, Anderson DK, Li Y, and Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43: 40–49, 1998.[Web of Science][Medline]
76. Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, and DeMarco V. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 49: 182–189, 2001.[Abstract/Free Full Text]
77. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, and Poellinger L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1. EMBO J 17: 6573–6586, 1998.[CrossRef][Web of Science][Medline]
78. Kambe T, Tada J, Chikuma M, Masuda S, Nagao M, Tsuchiya T, Ratcliffe PJ, and Sasaki R. Embryonal carcinoma P19 cells produce erythropoietin constitutively but express lactate dehydrogenase in an oxygen-dependent manner. Blood 91: 1185–1195, 1998.[Abstract/Free Full Text]
79. Kietzmann T, Fandrey J, and Acker H. Oxygen radicals as messengers in oxygen-dependent gene expression. News Physiol Sci 15: 202–208, 2000.[Abstract/Free Full Text]
80. Kim MJ, Bogic L, Cheung CY, and Brace RA. Expression of erythropoietin mRNA, protein and receptor in ovine fetal membranes. Placenta 22: 846–851, 2001.[CrossRef][Web of Science][Medline]
81. Kobayashi T, Yanase H, Iwanaga T, Sasaki R, and Nagao M. Epididymis is a novel site of erythropoietin production in mouse reproductive organs. Biochem Biophys Res Commun 296: 145–151, 2002.[CrossRef][Web of Science][Medline]
82. Kochling J, Curtin PT, and Madan A. Regulation of human erythropoietin gene induction by upstream flanking sequences in transgenic mice. Br J Haematol 103: 960–968, 1998.[CrossRef][Web of Science][Medline]
83. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, and Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279: 9899–9904, 2003.[Medline]
84. Koury MJ, Bondurant MC, Graber SE, and Sawyer ST. Erythropoietin messenger RNA levels in developing mice and transfer of ¹²⁵I-erythropoietin by the placenta. J Clin Invest 82: 154–159, 1988.[Web of Science][Medline]
85. Koury ST, Bondurant MC, and Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71: 524–527, 1988.[Abstract/Free Full Text]
86. Koury ST, Bondurant MC, Koury MJ, and Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77: 2497–2503, 1991.[Abstract/Free Full Text]
87. Kvietikova I, Wenger RH, Marti HH, and Gassmann M. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 23: 4542–4550, 1995.[Abstract/Free Full Text]
88. La Ferla K, Reimann C, Jelkmann W, and Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 16: 1811–1813, 2002.[Abstract/Free Full Text]
89. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, and Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466–1471, 2002.[Abstract/Free Full Text]
90. Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858–861, 2002.[Abstract/Free Full Text]
91. Lando D, Pongratz I, Poellinger L, and Whitelaw ML. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1 and the HIF-like factor. J Biol Chem 275: 4618–4627, 2000.[Abstract/Free Full Text]
92. Lee-Huang S, Lin JJ, Kung HF, Huang PL, Lee L, and Huang PL. The human erythropoietin-encoding gene contains a CAAT box, TATA boxes and other transcriptional regulatory elements in its 5' flanking region. Gene 128: 227–236, 1993.[CrossRef][Web of Science][Medline]
93. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, and Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82: 7580–7584, 1985.[Abstract/Free Full Text]
94. Madan A, Lin C, Hatch SL, and Curtin PT. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 85: 2735–2741, 1995.[Abstract/Free Full Text]
95. Magnanti M, Gandini O, Giuliani L, Gazzaniga P, Marti HH, Gradilone A, Frati L, Agliano AM, and Gassmann M. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood 98: 2872–2874, 2001.[Abstract/Free Full Text]
96. Mahon PC, Hirota K, and Semenza GL. FIH-1: a novel protein that interacts with HIF-1 and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675–2686, 2001.[Abstract/Free Full Text]
97. Makita T, Hernandez-Hoyos G, Chen THP, Wu H, Rothenberg EV, and Sucov HM. A developmental transition in definitive erythropoiesis: erythropoietin expression is sequentially regulated by retinoic acid receptors and HNF4. Genes Dev 15: 889–901, 2001.[Abstract/Free Full Text]
98. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, and Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8: 666–676, 1996.[CrossRef][Web of Science][Medline]
99. Marti HH and Bernaudin M. Function of erythropoietin in the brain. In: Erythropoietin: Molecular Biology and Clinical Use, edited by Jelkmann W. Johnson City, TN: Graham, 2003, p. 195–215.
100. Marti HH, Katschinski DM, Wagner KF, Schaffer L, Stier B, and Wenger RH. Isoform-specific expression of hypoxia-inducible factor-1 during the late stages of mouse spermiogenesis. Mol Endocrinol 16: 234–243, 2002.[Abstract/Free Full Text]
101. Masson N, Willam C, Maxwell PH, Pugh CW, and Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor- chains activated by prolyl hydroxylation. EMBO J 20: 5197–5206, 2001.[CrossRef][Web of Science][Medline]
102. Masson N and Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O₂ levels. J Cell Sci 116: 3041–3049, 2003.[Abstract/Free Full Text]
103. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr, Tabira T, and Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268: 11208–11216, 1993.[Abstract/Free Full Text]
104. Masuda S, Kobayashi T, Chikuma M, Nagao M, and Sasaki R. The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner. Am J Physiol Endocrinol Metab 278: E1038–E1044, 2000.[Abstract/Free Full Text]
105. Maxwell PH, Ferguson DJ, Osmond MK, Pugh CW, Heryet A, Doe BG, Johnson MH, and Ratcliffe PJ. Expression of a homologously recombined erythopoietin-SV40 T antigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 84: 1823–1830, 1994.[Abstract/Free Full Text]
106. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, and Ratcliffe PJ. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44: 1149–1162, 1993.[Web of Science][Medline]
107. Maxwell PH, Pugh CW, and Ratcliffe PJ. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 90: 2423–2427, 1993.[Abstract/Free Full Text]
108. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275, 1999.[CrossRef][Medline]
109. Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Burgel T, Jelkmann W, Acker H, and Fandrey J. Intracellular localisation of human HIF-1 hydroxylases: implications for oxygen sensing. J Cell Sci 116: 1319–1326, 2003.[Abstract/Free Full Text]
110. Metzen E, Zhou J, Jelkmann W, Fandrey J, and Brune B. Nitric oxide impairs normoxic degradation of HIF-1 by inhibition of prolyl hydroxylases. Mol Biol Cell 14: 3470–3481, 2003.[Abstract/Free Full Text]
111. Miyake T, Kung CK, and Goldwasser E. Purification of human erythropoietin. J Biol Chem 252: 5558–5564, 1977.[Abstract/Free Full Text]
112. Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, Kawauchi S, Ema M, Shibahara S, Udono T, Tomita K, Tamai M, Sogawa K, Yamamoto M, and Fujii-Kuriyama Y. HLF/HIF-2 is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22: 1134–1146, 2003.[CrossRef][Web of Science][Medline]
113. Moritz KM, Lim GB, and Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol Regul Integr Comp Physiol 273: R1829–R1844, 1997.[Abstract/Free Full Text]
114. Mukundan H, Resta TC, and Kanagy NL. 17beta-Estradiol decreases hypoxic induction of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 283: R496–R504, 2002.[Abstract/Free Full Text]
115. Nielsen OJ, Schuster SJ, Kaufman R, Erslev AJ, and Caro J. Regulation of erythropoietin production in a human hepatoblastoma cell line. Blood 70: 1904–1909, 1987.[Abstract/Free Full Text]
116. O'Rourke JF, Tian YM, Ratcliffe PJ, and Pugh CW. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1. J Biol Chem 274: 2060–2071, 1999.[Abstract/Free Full Text]
117. Peng J, Zhang L, Drysdale L, and Fong GH. The transcription factor EPAS-1/hypoxia-inducible factor 2 plays an important role in vascular remodeling. Proc Natl Acad Sci USA 97: 8386–8391, 2000.[Abstract/Free Full Text]
118. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, and Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the subunit. J Biol Chem 272: 11205–11214, 1997.[Abstract/Free Full Text]
119. Pugh CW and Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677–684, 2003.[CrossRef][Web of Science][Medline]
120. Pugh CW, Tan CC, Jones RW, and Ratcliffe PJ. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci USA 88: 10553–10557, 1991.[Abstract/Free Full Text]
121. Reissmann KR. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 5: 372–380, 1950.[Abstract/Free Full Text]
122. Richard DE, Berra E, Gothie E, Roux D, and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1 (HIF-1) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631–32637, 1999.[Abstract/Free Full Text]
123. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, and Eckardt KU. Expression of hypoxia-inducible factor-1 and -2 in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721–1732, 2002.[Abstract/Free Full Text]
124. Ruhenstroth-Bauer G. Versuche zum Nachweis eines spezifischen erythropoetischen Hormons. Arch Exp Pathol Pharmakol 211: 32–56, 1950.
125. Ryan HE, Lo J, and Johnson RS. HIF-1 is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005–3015, 1998.[CrossRef][Web of Science][Medline]
126. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, and Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635–4640, 1998.[Abstract/Free Full Text]
127. Salceda S and Caro J. Hypoxia-inducible factor 1 (HIF-1) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642–22647, 1997.[Abstract/Free Full Text]
128. Sang N, Fang J, Srinivas V, Leshchinsky I, and Caro J. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22: 2984–2992, 2002.[Abstract/Free Full Text]
129. Sasaki R, Masuda S, and Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci 16: 110–113, 2001.[Abstract/Free Full Text]
130. Schobersberger W, Hoffmann G, and Fandrey J. Nitric oxide donors suppress erythropoietin production in vitro. Pflügers Arch 432: 980–985, 1996.[CrossRef][Web of Science][Medline]
131. Schuster SJ, Badiavas EV, Costa-Giomi P, Weinmann R, Erslev AJ, and Caro J. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood 73: 13–16, 1989.[Abstract/Free Full Text]
132. Semenza GL. Hypoxia-inducible factor 1: master regulator of O₂ homeostasis. Curr Opin Genet Dev 8: 588–594, 1998.[CrossRef][Web of Science][Medline]
133. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474–1480, 2000.[Abstract/Free Full Text]
134. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71–103, 2000.[CrossRef][Web of Science][Medline]
135. Semenza GL, Dureza RC, Traystman MD, Gearhart JD, and Antonarakis SE. Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements. Mol Cell Biol 10: 930–938, 1990.[Abstract/Free Full Text]
136. Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, and Antonarakis SE. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci USA 88: 8725–8729, 1991.[Abstract/Free Full Text]
137. Semenza GL, Traystman MD, Gearhart JD, and Antonarakis SE. Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl Acad Sci USA 86: 2301–2305, 1989.[Abstract/Free Full Text]
138. Semenza GL and Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447–5454, 1992.[Abstract/Free Full Text]
139. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62–S67, 2002.[CrossRef][Web of Science][Medline]
140. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98: 4044–4049, 2001.[Abstract/Free Full Text]
141. Sogawa K, Numayama-Tsuruta K, Ema M, Abe M, Abe H, and Fujii-Kuriyama Y. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc Natl Acad Sci USA 95: 7368–7373, 1998.[Abstract/Free Full Text]
142. Stebbins CE, Kaelin WG Jr, and Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455–461, 1999.[Abstract/Free Full Text]
143. Stolze I, Berchner-Pfannschmidt U, Freitag P, Wotzlaw C, Rossler J, Frede S, Acker H, and Fandrey J. Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. Blood 100: 2623–2628, 2002.[Abstract/Free Full Text]
144. Tabata M, Tarumoto T, Ohmine K, Furukawa Y, Hatake K, Ozawa K, Hasegawa Y, Mukai H, Yamamoto M, and Imagawa S. Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression. J Cell Physiol 186: 260–267, 2001.[CrossRef][Web of Science][Medline]
145. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, and Karin M. Requirement for p38 in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 102: 221–231, 2000.[CrossRef][Web of Science][Medline]
146. Tan CC, Eckardt KU, Firth JD, and Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol Renal Fluid Electrolyte Physiol 263: F474–F481, 1992.[Abstract/Free Full Text]
147. Tian H, McKnight SL, and Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72–82, 1997.[Abstract/Free Full Text]
148. Tian H, Hammer RE, Matsumoto AM, Russell DW, and McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320–3324, 1998.[Abstract/Free Full Text]
149. Viault F. Sur l'augmentation considérable du nombre des globules rouge dans le sang chez les inhabitants des hauts plateaux de l'Amérique du Sud. C R Acad Sci Paris 111: 917–918, 1890.
150. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA 92: 5510–5514, 1995.[Abstract/Free Full Text]
151. Wenger RH. Cellular adaptation to hypoxia: O₂-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O₂-regulated gene expression. FASEB J 16: 1151–1162, 2002.[Abstract/Free Full Text]
152. Wenger RH, Kvietikova I, Rolfs A, Camenisch G, and Gassmann M. Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. Eur J Biochem 253: 771–777, 1998.[Web of Science][Medline]
153. Westgren M, Ek S, Remberger M, Ringden O, and Stangenberg M. Cytokines in fetal blood and amniotic fluid in Rh-immunized pregnancies. Obstet Gynecol 86: 209–213, 1995.[CrossRef][Web of Science][Medline]
154. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, and Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178, 1986.[CrossRef][Web of Science][Medline]
155. Wolff M, Fandrey J, and Jelkmann W. Microelectrode measurements of pericellular PO₂ in erythropoietin-producing human hepatoma cell cultures. Am J Physiol Cell Physiol 265: C1266–C1270, 1993.[Abstract/Free Full Text]
156. Wood SM, Gleadle JM, Pugh CW, Hankinson O, and Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 271: 15117–15123, 1996.[Abstract/Free Full Text]
157. Wu H, Lee SH, Gao J, Liu X, and Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126: 3597–3605, 1999.[Abstract]
158. Wu H, Liu X, Jaenisch R, and Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83: 59–67, 1995.[CrossRef][Web of Science][Medline]
159. Yamamoto Y, Sofikitis N, and Miyagawa I. Effects of erythropoietin, bromocryptine and hydralazine on testicular function in rats with chronic renal failure. Andrologia 29: 141–144, 1997.[Web of Science][Medline]
160. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, and Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273: 25381–25387, 1998.[Abstract/Free Full Text]
161. Yin H and Blanchard KL. DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms. Blood 95: 111–119, 2000.[Abstract/Free Full Text]
162. Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, and Okamura K. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 8: 441–446, 2002.[Abstract/Free Full Text]
163. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, and Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1. J Clin Invest 103: 691–696, 1999.[Web of Science][Medline]
164. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, Lin CS, Nikodem VM, Hempstead B, Flanders KC, Costantini F, and Noguchi CT. Erythropoietin receptor signalling is required for normal brain development. Development 129: 505–516, 2002.[Web of Science][Medline]
165. Zanjani ED, Peterson EN, Gordon AS, and Wasserman LR. Erythropoietin production in the fetus: role of the kidney and maternal anemia. J Lab Clin Med 83: 281–287, 1974.[Web of Science][Medline]

This article has been cited by other articles:

				J. F. Garvey, C. T. Taylor, and W. T. McNicholas Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation Eur. Respir. J., May 1, 2009; 33(5): 1195 - 1205. [Abstract] [Full Text] [PDF]

				O. Arjamaa and M. Nikinmaa Natriuretic peptides in hormonal regulation of hypoxia responses Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R257 - R264. [Abstract] [Full Text] [PDF]

				J.-S. Lin, Y.-S. Chen, H.-S. Chiang, and M.-C. Ma Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization J. Physiol., December 1, 2008; 586(23): 5757 - 5769. [Abstract] [Full Text] [PDF]

				J. Fandrey Erythropoietin Receptors on Tumor Cells: What Do They Mean? Oncologist, May 1, 2008; 13(suppl_3): 16 - 20. [Abstract] [Full Text] [PDF]

				S. Fishbane and A. Besarab Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1274 - 1282. [Abstract] [Full Text] [PDF]

				N. Paffett-Lugassy, N. Hsia, P. G. Fraenkel, B. Paw, I. Leshinsky, B. Barut, N. Bahary, J. Caro, R. Handin, and L. I. Zon Functional conservation of erythropoietin signaling in zebrafish Blood, October 1, 2007; 110(7): 2718 - 2726. [Abstract] [Full Text] [PDF]

				H. F. Bunn New agents that stimulate erythropoiesis Blood, February 1, 2007; 109(3): 868 - 873. [Abstract] [Full Text] [PDF]

				K. Heinicke, O. Baum, O. O. Ogunshola, J. Vogel, T. Stallmach, D. P. Wolfer, S. Keller, K. Weber, P. D. Wagner, M. Gassmann, et al. Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2006; 291(4): R947 - R956. [Abstract] [Full Text] [PDF]

				J. Fandrey A cordial affair - erythropoietin and cardioprotection Cardiovasc Res, October 1, 2006; 72(1): 1 - 2. [Full Text] [PDF]

				D. Burger, M. Lei, N. Geoghegan-Morphet, X. Lu, A. Xenocostas, and Q. Feng Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase Cardiovasc Res, October 1, 2006; 72(1): 51 - 59. [Abstract] [Full Text] [PDF]

				J. C. Chavez, O. Baranova, J. Lin, and P. Pichiule The Transcriptional Activator Hypoxia Inducible Factor 2 (HIF-2/EPAS-1) Regulates the Oxygen-Dependent Expression of Erythropoietin in Cortical Astrocytes J. Neurosci., September 13, 2006; 26(37): 9471 - 9481. [Abstract] [Full Text] [PDF]

				J. Fandrey, T. A. Gorr, and M. Gassmann Regulating cellular oxygen sensing by hydroxylation Cardiovasc Res, September 1, 2006; 71(4): 642 - 651. [Abstract] [Full Text] [PDF]

				V. H. Haase Hypoxia-inducible factors in the kidney Am J Physiol Renal Physiol, August 1, 2006; 291(2): F271 - F281. [Abstract] [Full Text] [PDF]

				A. M. Evans AMP-activated protein kinase and the regulation of Ca2+ signalling in O2-sensing cells J. Physiol., July 1, 2006; 574(1): 113 - 123. [Abstract] [Full Text] [PDF]

				H. F. Bunn Epo regulation: a 3-dimensional challenge Blood, June 1, 2006; 107(11): 4198 - 4199. [Full Text] [PDF]

				C. Dame, K. M. Kirschner, K. V. Bartz, T. Wallach, C. S. Hussels, and H. Scholz Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene Blood, June 1, 2006; 107(11): 4282 - 4290. [Abstract] [Full Text] [PDF]

				O. O. Ogunshola, V. Djonov, R. Staudt, J. Vogel, and M. Gassmann Chronic excessive erythrocytosis induces endothelial activation and damage in mouse brain Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R678 - R684. [Abstract] [Full Text] [PDF]

				H. Acker The oxygen sensing signal cascade under the influence of reactive oxygen species Phil Trans R Soc B, December 29, 2005; 360(1464): 2201 - 2210. [Abstract] [Full Text] [PDF]

				A. Maloyan, L. Eli-Berchoer, G. L. Semenza, G. Gerstenblith, M. D. Stern, and M. Horowitz HIF-1{alpha}-targeted pathways are activated by heat acclimation and contribute to acclimation-ischemic cross-tolerance in the heart Physiol Genomics, September 21, 2005; 23(1): 79 - 88. [Abstract] [Full Text] [PDF]

				L. P. Thompson and Y. Dong Chronic Hypoxia Decreases Endothelial Nitric Oxide Synthease Protein Expression in Fetal Guinea Pig Hearts Reproductive Sciences, September 1, 2005; 12(6): 388 - 395. [Abstract] [PDF]

				P. La Padula and L. E. Costa Effect of sustained hypobaric hypoxia during maturation and aging on rat myocardium. I. Mechanical activity J Appl Physiol, June 1, 2005; 98(6): 2363 - 2369. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (59) Citing Articles via Google Scholar Google Scholar Articles by Fandrey, J. Search for Related Content PubMed PubMed Citation Articles by Fandrey, J.